Abiraterone-Rechallenge Study for CRPC Patients (ABI-RE)

To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.


Study Type: Interventional
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA
Estimated Enrollment: 25
Study Start Date: January 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Abiraterone